Abstract: The particle sensor device comprises a substrate, a photodetector, a dielectric on or above the substrate, a source of electromagnetic radiation, and a through-substrate via in the substrate. The through-substrate via is exposed to the environment, in particular to ambient air. A waveguide is arranged in or above the dielectric so that the electromagnetic radiation emitted by the source of electromagnetic radiation is coupled into a portion of the waveguide. A further portion of the waveguide is opposite the photodetector, so that said portions of the waveguide are on different sides of the through-substrate via, and the waveguide traverses the through-substrate via.

Abstract: The present invention relates to polymeric particles comprising a biodegradable polymer, and at least one microorganism in a total concentration of at least 108 CFU/g dry weight that is stable for at least 35 weeks at 30° C. and optionally additional carriers and additives as well as to methods for producing polymeric particles and use thereof.

Abstract: A particulate matter sensor system for sensing particulate matter in a fluid includes a substrate and a cover disposed on the substrate. The cover defines at least a portion of a flow path through the microfluidic system. The sensor system includes a particulate matter sensor disposed in an interior space between the cover and the substrate. The particulate matter sensor includes an integrated sensor device electrically connected to the substrate. The flow path is defined through the particulate matter sensor. The sensor system includes a fluid circulation device disposed in the interior space between the cover and the substrate and configured to cause fluid to flow along the flow path through the microfluidic system.

Abstract: The present invention relates to novel inhibitors of adipose triglyceride lipase (ATGL) having an improved inhibitory activity against human ATGL (hATGL) as well as pharmaceutical compositions comprising these inhibitors, and their therapeutic use, particularly in the treatment or prevention of a lipid metabolism disorder, including, e.g., obesity, non-alcoholic fatty liver disease, type 2 diabetes, insulin resistance, glucose intolerance, hypertriglyceridemia, metabolic syndrome, cardiac and skeletal muscle steatosis, congenital generalized lipodystrophy, familial partial lipodystrophy, acquired lipodystrophy syndrome, atherosclerosis, or heart failure.

Abstract: The disclosed subject matter relates to a measuring device for measuring the flow velocity of a flowing fluid, comprising a first measuring element, which is configured to measure the flow velocity of the fluid and includes an interface that can be exposed to the flowing fluid, a second measuring element, which is configured to measure a characteristic property of the fluid and includes an interface that can be exposed to the flowing fluid, and an evaluation unit, which is connected to the first and second measuring elements and configured to correct the flow velocity, measured by the first measuring element, by the influence of the property of the fluid, measured by the second measuring element, on the measurement of the flow velocity. The disclosed subject matter furthermore relates to a measuring probe for such a measuring device.

Abstract: The disclosed subject matter relates to a method and a system for determining a position of a movable agent device in a reflective environment of which a geometric model is known and in which at least one anchor device has a predetermined position, comprising: transmitting a first and a second ultra-wideband pulse signal via a first and a second uni-directional antenna of the anchor device, respectively, and receiving respective received signals via an omni-directional antenna of the agent device; defining a set of candidate positions within said geometric model, and, for each candidate position, calculating a set of multipath components as a function of the geometric model, directivities of the uni-directional antennas and the position of the anchor device; determining a deviation measure between the calculated multipath components and said received signals; and obtaining the position of the agent device as the candidate position with the minimum deviation measure.

Abstract: The present invention relates to a method for producing 2-O-glyceryl-?-D-glucopyranoside (?GG; FIG. 1) from a glucosyl donor and a glucosyl acceptor comprising the steps: providing a sucrose phosphorylase (EC 2.4.1.7), incubating said sucrose phosphorylase with a mixture comprising a glucosyl donor and glycerol as glucosyl acceptor and isolating and/or purifying 2-O-glyceryl-?-D-glucopyranoside.

Abstract: An electrode for an electrochemical element with an organic electrolyte includes a polymeric material containing or composed of subunits according to general formulae (I) and/or (II): wherein n is an integer ?2, Y represents an amide group (—NH—CO— or —CO—NH—), an ester group (—O—CO— or —CO—O—) or a urethane group (—NH—CO—O— or —O—CO—NH—), R1, R2, R3 and R4 each independently represent H, alkyl (preferably —CH3, —C2H5), Alkoxy-(preferably —OCH3, —OC2H5), -halogen or —CN, Ar1 and Ar4 independently represent a bridging aryl group, Ar2 and Ar3 independently represent a non-bridging aryl group, and R5 is a bridging alkyl, alkene or aryl group, wherein Ar1 and Ar4 in structures (I) and (II) independently represent a bridging aryl group.

Abstract: A device for the transcutaneous, in vivo measurement of the concentration of at least one analyte in a living organism includes a catheter which can be introduced into the organism, and a luminescence indicator, which is immobilized on the catheter and which reacts to a change in the concentration of the at least one analyte to be measured with a change in at least one optical property. The luminescence indicator is transcutaneously connected to a source for providing an excitation radiation and a detector for detecting the measuring radiation. The luminescence indicator is immobilized on the outer circumference of the catheter, which is used to dispense a fluid medium, for example a medication, into the organism or to drain a body fluid.

Abstract: The invention refers to a library of bidirectional expression cassettes or expression vectors comprising a repertoire of bidirectional promoter sequences, each expression cassette comprising a promoter sequence operably linked to a first gene in one direction, and operably linked to an oppositely oriented second gene in the other direction which is different from the first gene, and bidirectional Pichia pastoris or CHO cells promoter sequences. The invention further refers to a method of screening or selecting a bidirectional promoter suitable for expressing at least two GOI in a host cell and a kit comprising a) an expression cassette consisting of the first and second genes and a stuffer sequence separating them, which stuffer sequence comprises a recognition site for a type IIS restriction enzyme at both ends; b) the type IIS restriction enzyme; c) and a repertoire of promoter, preferably a promoter library including bidirectional promoters.

Abstract: A method a described which includes depositing a first component of a multicomponent system by means of an inkjet process, and depositing a second component of the multicomponent system by means of an inkjet process.

Abstract: An electronic device includes a synchronous rectification circuit having an actively controlled switching element through which resonant current flows during operation. The actively controlled switching element is disposed in a package which adds stray inductance to a main current path of the synchronous rectification circuit. The electronic device also includes a fixed inductor magnetically coupled to the stray inductance or an additional inductance in series with the stray inductance so that the fixed inductor is not in the main current path of the synchronous rectification circuit and change in current through the inductance to which the fixed inductor is magnetically coupled induces a reference voltage at the fixed inductor which is in phase with a zero crossing point of the resonant current at different switching frequencies of the actively controlled switching element. A corresponding method of controlling the electronic device is also described.

Abstract: A mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter of the wild type Pichia pastoris AOX1 promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of: a) a transcription factor binding site (TFBS), b) nucleotides 170 to 235 (?784 to ?719), nucleotides 170 to 191 (?784 to ?763), nucleotides 192 to 213 (?762 to ?741), nucleotides 192 to 210 (?762 to ?744), nucleotides 207 to 209 (?747 to ?745), nucleotides 214 to 235 (?740 to ?719), nucleotides 304 to 350 (?650 to ?604), nucleotides 364 to 393 (?590 to ?561), nucleotides 434 to 508 (?520 to ?446), nucleotides 509 to 551 (?445 to ?403), nucleotides 552 to 560 (?402 to ?394), nucleotides 585 to 617 (?369 to ?337), nucleotides 621 to 660 (?333 to ?294), nucleotides 625 to 683 (?329 to ?271), nucleotides 736 to 741 (?218 to ?213), nucleotides 737 to 738 (?217 to ?216), nucleotides 726 to 755 (?228 to ?199), nucleotides 784 to 800 (?170 to ?154) or nucleotides 823 to 861 (?131 to ?93) of Seq ID No.

Abstract: A compound of formula (I) as defined herein is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, and diabetes and pharmaceutical compositions of the same. Also, a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. The method includes in vitro assays of compounds using ATGL and/or HSL, and cellular assays wherein inhibition is followed by observing indicators of efficacy. Also, methods for treatment or prevention of a condition involving cachexia, stroke, artherosclerosis, coronary artery disease, diabetes, preferably diabetes type II by administering a pharmaceutical composition comprising an agent which is able to inhibit ATGL. Also contemplated herein, are compositions comprising one or more ATGL-inhibiting agents optionally in combination with one or more lipase inhibitors or inhibitors of inflammatory cytokines.

Abstract: Method for compensating illumination deficiencies in microscopic “shape from focus (SFF)”, wherein firstly the reflectance of the scene is estimated by way of a projector-camera system and then microscopic “shape from focus (SFF)” is applied to a stack of reflectance maps rather than to the original image data.

Abstract: A mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter of the wild type Pichia pastoris AOX1 promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of: a) a transcription factor binding site (TFBS), b) nucleotides 170 to 235 (?784 to ?719), nucleotides 170 to 191 (?784 to ?763), nucleotides 192 to 213 (?762 to ?741), nucleotides 192 to 210 (?762 to ?744), nucleotides 207 to 209 (?747 to ?745), nucleotides 214 to 235 (?740 to ?719), nucleotides 304 to 350 (?650 to ?604), nucleotides 364 to 393 (?590 to ?561), nucleotides 434 to 508 (?520 to ?446), nucleotides 509 to 551 (?445 to ?403), nucleotides 552 to 560 (?402 to ?394), nucleotides 585 to 617 (?369 to ?337), nucleotides 621 to 660 (?333 to ?294), nucleotides 625 to 683 (?329 to ?271), nucleotides 736 to 741 (?218 to ?213), nucleotides 737 to 738 (?217 to ?216), nucleotides 726 to 755 (?228 to ?199), nucleotides 784 to 800 (?170 to ?154) or nucleotides 823 to 861 (?131 to ?93) of Seq ID No.

Abstract: The present invention relates to pre-catalysts for olefin metathesis and composition involving these pre-catalysts.

Abstract: The present invention relates to a novel polymeric material with enhanced hydrophilicity for medical use comprising a biocompatible polyester material selected from the group consisting of poly(hydroxyalkanoate)s, poly(lactic acid)s, poly(glycolic acid)s, poly(caprolactone)s and copolymers and blends thereof, wherein the biocompatible polyester material is crosslinked with a functionalized poly(alkylene oxide) having at least two functional groups independently selected from the group consisting of azido-formate and alkanoyl azide. The novel polymeric material with enhanced hydrophilicity is useful as a biocompatible material in a variety of medical applications, including medical implants, bioresorbable implants, tissue engineering, and controlled release.

Abstract: The present invention relates to a novel polymeric material with enhanced hydrophilicity for medical use comprising a biocompatible polyester material selected from the group consisting of poly(hydroxyalkanoate)s, poly(lactic acid)s, poly(glycolic acid)s, poly(caprolactone)s and copolymers and blends thereof, wherein the biocompatible polyester material is crosslinked with a functionalized poly(alkylene oxide) having at least two functional groups independently selected from the group consisting of azido-formate and alkanoyl azide. The novel polymeric material with enhanced hydrophilicity is useful as a biocompatible material in a variety of medical applications, including medical implants, bioresorbable implants, tissue engineering, and controlled release.

Abstract: The present invention relates to pre-catalysts for olefin metathesis and composition involving these pre-catalysts.